These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 17924835)

  • 1. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T; Sugimoto M; Shirai N; Ishizaki T
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
    Furuta T; Shirai N; Kodaira M; Sugimoto M; Nogaki A; Kuriyama S; Iwaizumi M; Yamade M; Terakawa I; Ohashi K; Ishizaki T; Hishida A
    Clin Pharmacol Ther; 2007 Apr; 81(4):521-8. PubMed ID: 17215846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
    Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
    Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
    Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenomical aspects of gastroesophageal reflux disease].
    Isaev VA
    Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
    Zhang L; Mei Q; Li QS; Hu YM; Xu JM
    J Clin Pharm Ther; 2010 Dec; 35(6):713-22. PubMed ID: 21054464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.